Positive CANON bladder cancer results

Here is the summary of the recent presentation friends:-

(http://www.viralytics.com/wp-content/uploads/2015/11/2015-SITC-Final-CANON-poster.pdf)


•CANON Phase I trial: Proof of concept of viral targeting, replication and tumor cell death following a single or multiple intravesicular administrations of CVA21 was achieved in patients from monotherapy Cohorts 1, 2 and 3.

•Clinical activity of CVA21 demonstrated by complete tumor response, viral replication (infectious virus increases in urine) and notable signs of viralinduced tumor inflammation.

•No evidence of systemic spread of CVA21 or development of serum neutralizing antibody.

•To date, intravesicular administration of CVA21 has been generally well tolerated with no Grade 2, 3 or 4 product-related AE’s

•Recruitment of monotherapy Cohorts 1, 2 and 3 is complete.

•Recruitment of mitomycin-C Combination Cohort is underway. •The observed tumor targeting and viral replication is likely to provide a strong signal in generating both a strong local and systemic anti-tumor immune response